Please contact us for more information or to learn if you are eligible to participate.
To determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients as measured by time to experiencing a first adjudicated Composite Clinical Outcome event, defined as any of the following: all-cause mortality, liver transplant, and significant hepatic events including hepatic decompensation events (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage) and confirmed increase of Model for End-stage Liver Disease (MELD) score from <12 to ≥15.
Principal Investigator | Fernando Membreno, MD |
Co-PI | John Rodriguez |
Sponsor | Madrigal Pharmaceuticals, Inc. |
Type of Trial | Interventional |